Related Experiment Videos
Zonisamide: a new antiepileptic drug
Grzegorz Sobieszek1, Kinga K Borowicz, Zaneta Kimber-Trojnar
1Department of Pathophysiology, Medical University, Jaczewskiego 8, PL 20-090 Lublin, Poland.
Polish Journal of Pharmacology
|January 6, 2004
Summary
Zonisamide (ZNS) is an effective antiepileptic drug for refractory epilepsy, offering a safe alternative when monotherapy fails. Further research is needed on its interactions with other drugs during polytherapy.
Area of Science:
- Pharmacology
- Neuroscience
- Epileptology
Background:
- Epilepsy treatment faces challenges with drug-resistant cases, affecting about one-third of patients.
- Polytherapy is often necessary when monotherapy proves insufficient for seizure control.
Purpose of the Study:
- To review the efficacy, pharmacokinetics, safety, and emerging applications of Zonisamide (ZNS) as an antiepileptic drug.
- To highlight ZNS's mechanisms of action and its role in managing refractory epilepsy.
Main Methods:
- Review of existing animal studies and clinical data on Zonisamide's efficacy and safety.
- Analysis of ZNS's pharmacological properties, including channel inhibition and neurotransmitter influence.
Main Results:
- Zonisamide effectively treats various seizure types and refractory epilepsy, with favorable pharmacokinetics and good tolerability.
- ZNS inhibits voltage-dependent Na(+) and T-type Ca(2+) channels, influences monoamine neurotransmission, and possesses free radical scavenging properties.
- Emerging research suggests ZNS may be beneficial for mania, neuropathic pain, Parkinson's disease, and migraine prophylaxis, alongside established neuroprotective effects.
Conclusions:
- Zonisamide is a valuable option for refractory epilepsy, demonstrating broad efficacy and a favorable safety profile.
- Further investigation into ZNS's interactions within polytherapy regimens is warranted due to inconsistent experimental data.
- Zonisamide shows promise for expanded therapeutic applications beyond epilepsy management.